P R O D U C T S P E C I F I C A T I O N S
Date: 2012-05-04 P R O D U C T N A M E P R O D U C T S P E C I F I C I T Y P R O D U C T C O D E P R O D U C T B U F F E R
50 mM Na-citrate, pH 6.0, 0.9 % NaCl, 0.05 % Sulfobetaine, 0.1 % NaN3 as a preservative
S H E L F L I F E A N D S T O R A G E A N A L Y T E D E S C R I P T I O N
Progesterone is produced after ovulation in the corpus luteum and during pregnancy in the placenta. It is also produced in the adrenal glands. In women, progesterone levels are relatively low during the preovulatory phase, rise after ovulation, and are elevated during the luteal phase. Progesterone levels tend to be < 2 ng/ml prior to ovulation, and > 5 ng/ml after ovulation. If pregnancy occurs, progesterone levels are initially maintained at luteal levels. With the onset of the luteal-placental shift in progesterone support of the pregnancy, levels start to rise further and may reach 100-200 ng/ml at term. After delivery and during lactation, progesterone levels are very low. Progesterone levels are relatively low in children and postmenopausal women. Adult males have levels similar to those in women during the follicular phase of the menstrual cycle. P A R A M E T E R S T E S T E D F R O M E A C H L O T P R O D U C T A P P E A R A N C E
Clear liquid, may turn opaque during storage
P R O D U C T C O N C E N T R A T I O N P R O D U C T A C T I V I T Y
80 – 120 % compared to reference in an IFMA-test
I E F - R A N G E P A R A M E T E R S D E T E R M I N E D O N L Y D U R I N G P R O D U C T R & D P H A S E C L A S S A N D S U B C L A S S A S S O C I A T I O N C O N S T A N T D I S S O C I A T I O N C O N S T A N T A F F I N I T Y C O N S T A N T D E T E R M I N A T I O N M E T H O D C R O S S - R E A C T I V I T I E S
21-hydroxyprogesterone (5%), 17-alpha-hydroxyprogesterone (2%), 11-alpha-hydroxyprogesterone (0,5%), 17-alpha-hydroxypregnenolone (0%), others not tested. Oy Medix Biochemica Ab Telephone Extranet Public website
Request your personal login ID by emailing to
E P I T O P E G R O U P
Two antibodies binding to the same, or closely located epitopes, belong to the same group and hence cannot be used as a pair in a sandwich assay. Epitope group numbering does not give any detailed information where the epitope is located. P A I R R E C O M M E N D A T I O N S
Please note that pair recommendations are based on results obtained in our laboratory. Equally good results may be obtained using other pairs and therefore these recommendations should be taken only as a directive. P R O D U C T S T A B I L I T Y T E M P E R A T U R E , D A Y S
Please note that the shelf life given on
page one is based on real time stability testing at +2-8 oC in the product buffer.
Stability testing is performed in the product buffer to see whether different temperatures affect the antigen binding, charge or composition of the antibody. The maximum duration of the test is 21 days, except for the +45 oC only 7 days.
p H , 1 4 D A Y S , + 4 o C
Stability testing is performed to see whether pH affects the antigen binding, charge or composition of the antibody during 14 days at +4 oC.
M I S C E L L A N E O U S
Coupling to carrier protein for immunization was done on carbon 6 in the steroid ring structure. R E F E R E N C E S Legal disclaimer
MedixMAB monoclonal antibodies meet their specifications if transported, stored and used according to the instructions for use. See also separate Notes on use and storage of monoclonal antibodies. If not otherwise agreed in writing all products are sold under General Delivery Terms. Other terms may apply if MedixMAB monoclonal antibodies are purchased from an official distributor of Medix Biochemica products. MedixMAB is a registered trademark of Medix Biochemica and may not be used or reproduced without Medix Biochemica’s written permission. Further information on products and methods is available from medixMAB website and extranet. Oy Medix Biochemica Ab Telephone Extranet Public website
Request your personal login ID by emailing to
Curing metastatic testicular cancer Lawrence H. Einhorn* Indiana University Medical Center, 535 Barnhill Drive, RT 473, Indianapolis, IN 46202-5289Contributed by Lawrence H. Einhorn, February 5, 2002This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected on May 1, 2001. Our initial studies with cisplatin ؉ vinblastine
Sandoz Inc. 506 Carnegie Center Drive, Suite 400 Princeton, NJ 08540 Phone +1 609 627 8500 Fax +1 609 627 8682 Sandoz launches lansoprazole delayed-release orally disintegrating tablets (ODT), an authorized generic version of PREVACID® SoluTab Princeton, New Jersey; October 18, 2010 - Sandoz today announced the introduction of lansoprazole delayed-release orally disintegrating tab